Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] price surged by 3.57 percent to reach at $0.04. The company report on February 19, 2021 that Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 4,390,244 shares of its common stock at a price to the public of $1.025 per share, less underwriting discounts and commissions. After giving effect to the option closing, the aggregate gross proceeds to Diffusion from the offering were approximately $34.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Diffusion.
H.C. Wainwright & Co. acted as the sole book-running manager for the offering.
A sum of 7121593 shares traded at recent session while its average daily volume was at 6.81M shares. Diffusion Pharmaceuticals Inc. shares reached a high of $1.23 and dropped to a low of $1.13 until finishing in the latest session at $1.16.
Guru’s Opinion on Diffusion Pharmaceuticals Inc. [DFFN]:
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.19 The Price to Book ratio for the last quarter was 2.58, with the Price to Cash per share for the same quarter was set at 0.21.
DFFN Stock Performance Analysis:
Diffusion Pharmaceuticals Inc. [DFFN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.15. With this latest performance, DFFN shares dropped by -10.77% in over the last four-week period, additionally plugging by 11.54% over the last 6 months – not to mention a rise of 187.63% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 46.89, with the RSI for the last a single of trading hit 42.72, and the three-weeks RSI is set at 49.38 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 1.0763, while it was recorded at 1.2560 for the last single week of trading, and 0.9835 for the last 200 days.
Insight into Diffusion Pharmaceuticals Inc. Fundamentals:
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
DFFN Stock EPS
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
Diffusion Pharmaceuticals Inc. [DFFN] Insider Position Details
There are presently around $6 million, or 9.80% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 2,832,739, which is approximately -5.214% of the company’s market cap and around 0.21% of the total institutional ownership; BLACKROCK INC., holding 830,471 shares of the stock with an approximate value of $0.96 million in DFFN stocks shares; and VANGUARD GROUP INC, currently with $0.46 million in DFFN stock with ownership of nearly 11.624% of the company’s market capitalization.
10 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 442,231 shares. Additionally, 12 investors decreased positions by around 371,565 shares, while 7 investors held positions by with 4,292,181 shares. The mentioned changes placed institutional holdings at 5,105,977 shares, according to the latest SEC report filing. DFFN stock had 5 new institutional investments in for a total of 267,889 shares, while 7 institutional investors sold positions of 186,678 shares during the same period.